Minna Sopo1, Hanna Sallinen1,2,3,4, Kirsi Hämäläinen5,6, Annukka Kivelä2,4, Seppo Ylä-Herttuala2,4, Veli-Matti Kosma5,6,7, Leea Keski-Nisula1,3, Maarit Anttila1,3. 1. Department of Gynecology, Kuopio University Hospital, Kuopio, Finland. 2. Department of Biotechnology and Molecular Medicine, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. 3. Institute of Clinical Medicine, School of Medicine, Gynaecology, University of Eastern Finland, Kuopio, Finland. 4. Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland. 5. Department of Pathology and Forensic Medicine, Kuopio University Hospital, Kuopio, Finland. 6. Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. 7. Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland.
Abstract
BACKGROUND: Antiangiogenic therapy, although part of standard treatment in ovarian cancer, has variable efficacy. Furthermore, little is known about the prognostic biomarkers and factors influencing angiogenesis in cancer tissue. We evaluated the expression of angiopoietin-2 and two endothelial tyrosine kinase receptors, Tie-1 and Tie-2, and assessed their value in the prediction of survival in patients with malignant epithelial ovarian cancer. We also compared the expression of these factors between primary high grade serous tumors and their distant metastasis. MATERIALS AND METHODS: We evaluated 86 women with primary epithelial ovarian cancer. Matched distal omental metastasis were investigated in 18.6% cases (N = 16). The expression levels of angiogenic factors were evaluated by immunohistochemistry in 306 specimens and by qRT-PCR in 111 samples. RESULTS: A high epithelial expression level of Tie-2 is a significant prognostic factor in primary high grade serous ovarian cancer. It predicted significantly shorter overall survival both in univariate (p<0.001) and multivariate survival analyses (p = 0.022). Low angiopoietin-2 expression levels in primary ovarian tumors were significantly associated with shorter overall survival (p = 0.015) in the univariate survival analysis. A low expression of angiopoietin-2 was also significantly related to high grade tumors, size of residual tumor after primary surgery and the recurrence of cancer (p = 0.008; p = 0.012; p = 0.018) in the whole study population. The expression of angiopoietin-2 and Tie-2 was stronger in distal omental metastasis than in primary high grade serous tumors in matched-pair analysis (p = 0.001; p = 0.002). CONCLUSIONS: The angiogenic factor, angiopoietin-2, and its receptor Tie-2 seem to be significant prognostic factors in primary epithelial ovarian cancer. Their expression levels are also increased in metastatic lesions in comparison with primary tumors.
BACKGROUND: Antiangiogenic therapy, although part of standard treatment in ovarian cancer, has variable efficacy. Furthermore, little is known about the prognostic biomarkers and factors influencing angiogenesis in cancer tissue. We evaluated the expression of angiopoietin-2 and two endothelial tyrosine kinase receptors, Tie-1 and Tie-2, and assessed their value in the prediction of survival in patients with malignant epithelial ovarian cancer. We also compared the expression of these factors between primary high grade serous tumors and their distant metastasis. MATERIALS AND METHODS: We evaluated 86 women with primary epithelial ovarian cancer. Matched distal omental metastasis were investigated in 18.6% cases (N = 16). The expression levels of angiogenic factors were evaluated by immunohistochemistry in 306 specimens and by qRT-PCR in 111 samples. RESULTS: A high epithelial expression level of Tie-2 is a significant prognostic factor in primary high grade serous ovarian cancer. It predicted significantly shorter overall survival both in univariate (p<0.001) and multivariate survival analyses (p = 0.022). Low angiopoietin-2 expression levels in primary ovarian tumors were significantly associated with shorter overall survival (p = 0.015) in the univariate survival analysis. A low expression of angiopoietin-2 was also significantly related to high grade tumors, size of residual tumor after primary surgery and the recurrence of cancer (p = 0.008; p = 0.012; p = 0.018) in the whole study population. The expression of angiopoietin-2 and Tie-2 was stronger in distal omental metastasis than in primary high grade serous tumors in matched-pair analysis (p = 0.001; p = 0.002). CONCLUSIONS: The angiogenic factor, angiopoietin-2, and its receptor Tie-2 seem to be significant prognostic factors in primary epithelial ovarian cancer. Their expression levels are also increased in metastatic lesions in comparison with primary tumors.
Authors: Bradley J Monk; Andrés Poveda; Ignace Vergote; Francesco Raspagliesi; Keiichi Fujiwara; Duk-Soo Bae; Ana Oaknin; Isabelle Ray-Coquard; Diane M Provencher; Beth Y Karlan; Catherine Lhommé; Gary Richardson; Dolores Gallardo Rincón; Robert L Coleman; Thomas J Herzog; Christian Marth; Arija Brize; Michel Fabbro; Andrés Redondo; Aristotelis Bamias; Marjan Tassoudji; Lynn Navale; Douglas J Warner; Amit M Oza Journal: Lancet Oncol Date: 2014-06-17 Impact factor: 41.316
Authors: Angela Coxon; James Bready; Hosung Min; Stephen Kaufman; Juan Leal; Dongyin Yu; Tani Ann Lee; Ji-Rong Sun; Juan Estrada; Brad Bolon; James McCabe; Ling Wang; Karen Rex; Sean Caenepeel; Paul Hughes; David Cordover; Haejin Kim; Seog Joon Han; Mark L Michaels; Eric Hsu; Grant Shimamoto; Russell Cattley; Eunju Hurh; Linh Nguyen; Shao Xiong Wang; Anthony Ndifor; Isaac J Hayward; Beverly L Falcón; Donald M McDonald; Luke Li; Tom Boone; Richard Kendall; Robert Radinsky; Jonathan D Oliner Journal: Mol Cancer Ther Date: 2010-10 Impact factor: 6.261
Authors: K Engels; A du Bois; P Harter; A Fisseler-Eckhoff; F Kommoss; R Stauber; M Kaufmann; V Nekljudova; S Loibl Journal: J Clin Pathol Date: 2009-01-06 Impact factor: 3.411
Authors: Suvi E Heinonen; Annukka M Kivelä; Jenni Huusko; Marike H Dijkstra; Erika Gurzeler; Petri I Mäkinen; Pia Leppänen; Vesa M Olkkonen; Ulf Eriksson; Matti Jauhiainen; Seppo Ylä-Herttuala Journal: Cardiovasc Res Date: 2013-06-10 Impact factor: 10.787
Authors: Camille L Duran; Lucia Borriello; George S Karagiannis; David Entenberg; Maja H Oktay; John S Condeelis Journal: Cancers (Basel) Date: 2021-11-16 Impact factor: 6.639
Authors: Patrick A Ott; Matthew Nazzaro; Kathleen L Pfaff; Evisa Gjini; Kristen D Felt; Jacquelyn O Wolff; Elizabeth I Buchbinder; Rizwan Haq; Ryan J Sullivan; Donald P Lawrence; David F McDermott; Mariano Severgnini; Anita Giobbie-Hurder; Scott J Rodig; F Stephen Hodi Journal: J Immunother Cancer Date: 2021-11 Impact factor: 13.751
Authors: Igor Maiborodin; Alfija Mansurova; Alexander Chernyavskiy; Alexander Romanov; Vladimir Voitcitctkii; Anna Kedrova; Alexander Tarkhov; Alena Chernyshova; Sergey Krasil'nikov Journal: J Pers Med Date: 2022-02-22